title: Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma.
abstract: Pleomorphic lobular carcinoma (PLC), a variant of invasive lobular carcinoma (ILC) is described as an aggressive tumor with poor prognosis. Multiple studies show lower overall survival for patients with PLC than for patients with classic ILC (cILC). We compared the clinicopathologic characteristics of PLC with those of cILC. All cases with a diagnosis of ILC, Nottingham grades 2 or 3 that were diagnosed between January 1, 1990, and December 31, 2010, were retrieved from pathology files in the institutional anatomic pathology database. The cases (N = 52) were reviewed to identify those meeting the criteria for PLC. An E-cadherin immunostain was used to confirm the lobular immunophenotype. Clinicopathologic data were assessed and analyzed. A control group (N = 103) of cILC, Nottingham grade 1, was selected, with 2 controls for each case, matched by age and year of diagnosis. PLC was associated more closely with in situ carcinoma (P = .03), and had lower progesterone receptor expression (P = .03) than cILC. Both disease-free survival and overall survival were similar between patients with PLC and matched cILC controls, and both depended on disease stage, tumor size, and lymph node status. PLC is similar to cILC in terms of patient survival and outcomes.
authors: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. Electronic address: nassar.aziza@mayo.edu.
authors: Sonia
authors: S
authors: Narendra
authors: Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
authors: Sarah M
authors: SM
authors: Jenkins
authors: Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL.
authors: Andras
authors: A
authors: Khoor
authors: Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL.
authors: Aziza
authors: A
authors: Nassar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D015820:Cadherins / Q000378:metabolism; D002278:Carcinoma in Situ / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins
keywords: Classic lobular carcinoma; Outcome; Pleomorphic lobular carcinoma; Survival